Study of leucine-rich alpha-2-glycoprotein-1 marker serum level in cases of malignant epithelial ovarian tumors


  • Abd Elfatah Agameia Department of Obstetrics and Gynecology, Faculty of Medicine, Alexandria University, Egypt
  • Rania Shafik Swelem Department of Clinical and Chemical pathology, Faculty of medicine, Alexandria University, Egypt
  • Hossam Hassan El Sokkary Department of Obstetrics and Gynecology, Faculty of Medicine, Alexandria University, Egypt
  • Ghada Shehata Elsayed Department of Obstetrics and Gynecology, Faculty of Medicine, Alexandria University, Egypt



Epithelial ovarian tumors, Leucine-rich alpha-2-glycoprotein-1


Background: The aim of this study was to compare the level of LRG1 in epithelial ovarian cancer (EOC) cases with benign ovarian masses and to evaluate results in relation to CA125.

Methods: An observational prospective controlled study was done on 70 patients admitted to El Shatby Maternity University Hospital, Oncology department categorized as follows: study group (group I) included 35 patients, with epithelial ovarian malignancy confirmed by histopathological examination and control group (group Il) included 35 patients with benign ovarian tumors confirmed by histopathological examination. Determination of Serum LRGI level by using enzyme-linked immuno sorbent assay with CA125 tumor marker analysis were done for all cases of both groups.

Results: As regard comparison between the two studied groups according to CA125 and LRGI. CA125 in group I ranged from 14.90 to 4600 with a mean value 856.73±1104.03, in group II ranged from 7.45 to 523 with a mean value of 51.97±86.14. LRGI in group I ranged from 62.46 to 653.98 with a mean value of 130.86±119.78, in group Il ranged from 47.73 to 261.78 with a mean value of 77.35±38.75. There was statistically significant difference between the two studied groups regarding CA125 and LRGI (p≤0.05).

Conclusions: LRG1 can be used as promising tumor marker to diagnose epithelial malignant ovarian cancer with or without CA125 tumor marker as it was significantly higher in epithelial ovarian cancer patients.


Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer J Clini. 2018;68(6):394-424.

Doubeni CA, Doubeni AR, Myers AE. Diagnosis and Management of Ovarian Cancer. Am Fam Physician. 2016;93(11):937-44.

Haupt H, Baudner S. Isolation and characterization of an unknown, leucine rich 3.1-S- alpha2-glycoprotein from human serum. Hoppe Seyler Z Physiol Chem. 1977;358(6):639–46.

Kentsis A, Ahmed S, Kurek K, Brennan E, Bradwin G, Steen H, et al. Detection and diagnostic value of urine leucine-rich α-2-glycoprotein in children with suspected acute appendicitis. Ann Emerg Med. 2012;60(1):78–83.

Serada S, Fujimoto M, Terabe F, Iijima H, Shinzaki S, Matsuzaki S, et al. Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis. Inflamm Bowel Dis. 2012;18(11):2169–79.

Furukawa K, Kawamoto K, Eguchi H, Tanemura M, Tanida T, Tomimaru Y, et al. Clinicopathological Significance of Leucine-Rich α2-Glycoprotein-1 in Sera of Patients With Pancreatic Cancer. Pancreas. 2015;44(1):93–8.

Uen YH, Lin KY, Sun DP, Liao CC, Hsieh MS, Huang YK, et al. Comparative proteomics, network analysis and post-translational modification identification reveal differential profiles of plasma con a-bound glycoprotein biomarkers in gastric cancer. J Proteomics. 2013;83:197–213.

He X, Wang Y, Zhang W, Li H, Luo R, Zhou Y, et al. Screening differential expression of serum proteins in AFP-negative HBV-related hepatocellular carcinoma using iTRAQ -MALDI-MS/MS. Neoplasma. 2014;61(1):17–26.

Wu RC, Yu CS, Liu KC, Huang HY, Ip SW, Lin JP, et al. Citosol (thiamylal sodium) triggers apoptosis and affects gene expressions of murine leukemia raw 264.7 cells. Hum Exp Toxicol. 2012;31:771–9.

Zhang J, Zhu L, Fang J, Ge Z, Li X. LRG1 modulates epithelial-mesenchymal transition and angiogenesis in colorectal cancer via HIF-1α activation. J Exp Clin Cancer Res. 2016;35:29.

Zhong D, He G, Zhao S, Li J, Lang Y,Ye W, Li Y, Jiang C, Li X. LRG1 modulates invasion and migration of glioma cell lines through TGF-beta signaling pathway. Acta Histochem. 2015;117(6):551–8.

Zavesky L, Jancarkova N, Kohoutova M. Ovarian cancer: origin and factors involved in carcinogenesis with potential use in diagnosis, treatment and prognosis of the disease. Neoplasma. 2011;58(6):457-68.

Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2011;61(2):133-4.

Ladd JJ, Busald T, Johnson MM, Zhang Q, Pitteri SJ, Wang H, et al. Increased plasma levels of the apc-interacting protein mapre1, lrg1, and igfbp2 preceding a diagnosis of colorectal cancer in women. 2012;5(4):655-64.

Lindén M, Lind SB, Mayrhofer C, Segersten U, Wester K, Lyutvinskiy Y, et al. Proteomic analysis of urinary biomarker candidates for nonmuscle invasive bladder cancer. Proteomics. 2012;12(1):135–44.

Andersen JD, Boylan KL, Jemmerson R, et al. Leucine-rich alpha-2-glycoprotein-1 is upregulated in sera and tumors of ovarian cancer patients. J Ovarian Res. 2010;3:21.

Wu J, Yin H, Zhu J, Buckanovich RJ, Thorpe JD, Dai J, et al. Validation of LRG1 as a Potential Biomarker for Detection of Epithelial Ovarian Cancer by a Blinded Study. PLoS ONE. 2015;10(3):e0121112.






Original Research Articles